Abstract:Objective:To establish correction model of the sampling time error on the blood trough concentration of tacrolimus in non-sustained-release dosage form for renal transplant recipient and improve the accuracy of drug dose assessment and clinical adjustment in renal transplant recipients.Methods:Visit records of 206 outpatients in the Department of Transplantation, Nanfang Hospital, Southern Medical University were retrospectively collected from October 15, 2022 to October 30, 2022. The distribution of sampling time of tacrolimus blood drug concentration was described and the time range of correction was determined. Twenty inpatients after renal transplantation in the Department of Transplantation, Nanfang Hospital, Southern Medical University from October 1, 2022 to November 30, 2022 were prospectively included, and their demography data, laboratory test results during follow-ups, and CYP3A5 genotype were collected. The patients took tacrolimus in non-sustained-release dosage form every 12 h starting from 19∶30 on the day of admission. Peripheral blood samples were collected from the patients on the second day of admission at 7∶30 and on the third day at 6∶00-10∶00 every 30 minutes to test the blood concentration of tacrolimus. Using the collection time as the independent variable and the blood tacrolimus concentration as the dependent variable, a simple linear regression was performed to fitting a linear model of tacrolimus blood concentration-sampling time. Multiple linear regression was performed to analyze the influencing factors of the tacrolimus metabolic rate within a specific period and generate the regression equation.Results:The 206 outpatients aged (46±13) years, including 131 males (63.6%). The time gap [ M ( Q1, Q3)] between the sampling time of the follow-up outpatients and standard C 12 was 24 (13.0, 46.5) min, and the maximum time gap was 135 min. The 20 enrolled inpatients aged (45±12) years, including 15 males (75.0%). There was no significant difference in the blood concentration of tacrolimus collected at 7∶30 on the second (7.87±2.21)ng/ml and third days (7.84±2.33)ng/ml after admission of the enrolled inpatients ( P=0.917), and the blood tacrolimus concentration rhythm was stable in the trial. The plasma concentration of C 10.5-C 14.5 was linearly related to the time, with R2 [ M ( Q1, Q3)] 0.88 (0.85, 0.92) and all P<0.05. The metabolic rate of tacrolimus during C 10.5-C 14.5=0.984+0.090×basic concentration of tacrolimus (ng/ml)-0.036×body mass index+0.489×CYP3A5 genotype-0.007×hemolobin(g/L)-0.035×alanine aminotransferase (U/L)+0.143×total cholesterol (mmol/L)+0.027×total bilirubin (μmol/L), with R2=0.85. Conclusion:This study propose a correction model for tacrolimus (non-sustained-release dosage form) trough concentration around C 12, which is helpful for clinicians to easily and accurately assess renal transplant recipients′ tacrolimus exposure.

Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children

Limited Sampling Strategy for Estimating Individual Exposure of Tacrolimus in Pediatric Kidney Transplant Patients.

A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts

Limited Sampling Strategy for the Estimation of Tacrolimus Area under the Concentration-Time Curve in Chinese Adult Liver Transplant Patients

A Limited Sampling Strategy for Tacrolimus in Liver Transplant Patients

The Pharmacokinetics of Tacrolimus in Peripheral Blood Mononuclear Cells and Limited Sampling Strategy for Estimation of Exposure in Renal Transplant Recipients

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients

Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients

Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation

Pharmacokinetics of Once Daily Prolonged-Release Formulation of Tacrolimus in Children with Primary Nephrotic Syndrome.

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients

Population Pharmacokinetics and Dosage Optimization of Tacrolimus in Pediatric Patients with Nephrotic Syndrome

Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients

Prediction of the Intra-T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling

Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome

Corrigendum: Impact of Sampling Time Variability on Tacrolimus Dosage Regimen in Pediatric Primary Nephrotic Syndrome: Single-center, Prospective, Observational Study

Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction

Choosing the Right Dose of Tacrolimus

Population Pharmacokinetic Analysis Of Tacrolimus Early After Chinese Pediatric Liver Transplantation

Correction model of the sampling time error on the blood trough concentration of tacrolimus in non-sustained-release dosage form for renal transplant recipients